



Media release – for immediate release

Prof. Michel Lazdunski appointed as Vice-President Research of Moleac

Singapore, 11th February 2009: Moleac Pte. Ltd announced that Prof. Michel Lazdunski has been appointed as Vice-President Research of Moleac. He will be in charge of future studies on the mechanism of action of the company's flagship product Neuroaid in treating stroke.

“We are more than happy to welcome Prof. Michel Lazdunski to join Moleac. Michel's appointment comes at a key time in our maturation, as we have demonstrated the efficacy of NeuroAid for stroke recovery and want to identify active ingredients within our drug, which is a mixture of 14 components”, said David Picard, the CEO of Moleac: “Michel has been a member of Moleac's Scientific Advisory Board from inception of the Company and has demonstrated extraordinary commitment to Moleac over the past years. Michel will now lead the company's R&D and will manage its collaborative research”.

As a world-renowned specialist of pharmacology of ion channels, Prof. Lazdunski has made internationally-recognized contributions to basic and applied research in pharmacology and pathology. These range from understanding the mechanisms underlying cerebral ischemia, cardiac arrhythmia, convulsions and pain perception, to the mechanisms of anti-hypertensive, anti-diabetics, and anesthetics. Over the last 30 years, Michel Lazdunski and his team have not only elucidated the molecular properties of the structure and functioning of ion channels; but have also used a highly diverse and sophisticated pharmacological arsenal to shed new light on the role of these ion channels and other ion transport systems in a wide range of diseases and pathological conditions.

Michel Lazdunski received the CNRS Gold Medal, the highest French scientific distinction. He has received several prestigious awards, such as the Grand Prix of the French Academy of Sciences for biological research (Charles Leopold Mayer Prize), the International Society for Cardiac Research Prize, the Bristol-Myers Foundation



Neuroscience Award, the Athena Foundation - Institut de France Prize, the Grand Prix of the French Academy of Sciences for research of importance to the medical field, the Grand Prix of the French Foundation for Medical Research. Michel Lazdunski is a member of several academies, including the Academia Europaea and the French Academy of Sciences and the Belgian Academy of Medicine.

- End -

About Moleac

Moleac is a Singapore-based biopharmaceutical company that dedicates itself in finding and developing new medicines for the unmet needs of patients worldwide. Its first product NeuroAid, derived from Traditional Chinese Medicine, has already had excellent clinical results in China and nowadays is sold in more than 30 countries in the world.

Contact details:

Chan Yiu Lin

Greener Grass Communications

Mobile: (65) 9-7655897

yiulin@greenergrass.com.sg

news@moleac.net